Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Net income | -$854K | -$13.1M | -$16.5M | -$10.4M |
| EPS (diluted) | -$0.03 | $0.48 | -$0.56 | -$0.33 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$469K | -$3.86M | -$5.07M | -$3.69M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total assets | $48.7K | $4.77M | $1.32M | $7.34M |
| Total liabilities | $986K | $1.34M | $681K | $1.43M |
| Shareholders' equity | -$937K | $3.44M | $643K | $5.91M |
| Retained earnings | -$992K | -$14.1M | -$30.6M | -$41.0M |
| Shares (wtd avg diluted) | 26.8M | 27.3M | 29.5M | 31.7M |
Every figure is extracted from Telomir Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.